These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 9059793)
1. N30 wave of somatosensory evoked potentials in Parkinson's disease: a pharmacological approach. Traversa R; Pierantozzi M; Semprini R; Loberti M; Peppe A; Cicardi MC; Stanzione P Electroencephalogr Clin Neurophysiol Suppl; 1996; 46():193-200. PubMed ID: 9059793 [No Abstract] [Full Text] [Related]
2. N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study. Traversa R; Pierantozzi M; Semprini R; Loberti M; Cicardi MC; Bassi A; Stanzione P J Neural Transm Suppl; 1995; 45():177-85. PubMed ID: 8748624 [TBL] [Abstract][Full Text] [Related]
3. [Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease]. Castillo JL; Miranda CM; Araya F; Sáez D Rev Med Chil; 1996 Mar; 124(3):301-6. PubMed ID: 9008941 [TBL] [Abstract][Full Text] [Related]
4. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087 [TBL] [Abstract][Full Text] [Related]
5. Somatosensory evoked potentials at rest and during movement in Parkinson's disease: evidence for a specific apomorphine effect on the frontal N30 wave. Cheron G; Piette T; Thiriaux A; Jacquy J; Godaux E Electroencephalogr Clin Neurophysiol; 1994 Nov; 92(6):491-501. PubMed ID: 7527767 [TBL] [Abstract][Full Text] [Related]
6. Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients. de Mari M; Margari L; Lamberti P; Iliceto G; Ferrari E J Neural Transm Suppl; 1995; 45():171-6. PubMed ID: 8748623 [TBL] [Abstract][Full Text] [Related]
7. Dopamine agonists in the treatment of Parkinson's disease. Bonuccelli U; Pavese N Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315 [TBL] [Abstract][Full Text] [Related]
8. The abnormality of N30 somatosensory evoked potential in idiopathic Parkinson's disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations. Onofrj M; Fulgente T; Malatesta G; Ferracci F; Thomas A; Curatola L; Bollettini F; Ragno M Mov Disord; 1995 Jan; 10(1):71-80. PubMed ID: 7885358 [TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease. Clinical and electrophysiological evaluation. Al-Bunyan MA Saudi Med J; 2000 Jan; 21(1):72-5. PubMed ID: 11533754 [TBL] [Abstract][Full Text] [Related]
11. Electrophysiological and clinical desensitization to apomorphine administration in parkinsonian patients undergoing stereotaxic neurosurgery. Stefani A; Mazzone P; Bassi A; Bernardi G; Altibrandi MG; Peppe A; Pierantozzi M; Stanzione P Exp Neurol; 1999 Mar; 156(1):209-13. PubMed ID: 10192792 [TBL] [Abstract][Full Text] [Related]
12. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
13. Spike-timing-related plasticity is preserved in Parkinson's disease and is enhanced by dopamine: evidence from transcranial magnetic stimulation. Rodrigues JP; Walters SE; Stell R; Mastaglia FL; Thickbroom GW Neurosci Lett; 2008 Dec; 448(1):29-32. PubMed ID: 18952149 [TBL] [Abstract][Full Text] [Related]
14. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease. Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362 [TBL] [Abstract][Full Text] [Related]
15. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease. Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061 [TBL] [Abstract][Full Text] [Related]
16. The effects of apomorphine on attentional processing in Parkinson's disease. Růzicka E; el Massioui F; Pillon B; Dubois B; Renault B; Agid Y Sb Lek; 1999; 100(2):85-99. PubMed ID: 11220166 [TBL] [Abstract][Full Text] [Related]
18. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Chen JJ; Obering C Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444 [TBL] [Abstract][Full Text] [Related]
19. Subthalamic somatosensory evoked potentials in Parkinson's disease. Pesenti A; Priori A; Locatelli M; Egidi M; Rampini P; Tamma F; Caputo E; Chiesa V; Barbieri S Mov Disord; 2003 Nov; 18(11):1341-5. PubMed ID: 14639678 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. Baas H; Harder S; Bürklin F; Demisch L; Fischer PA Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]